GLP-1 Receptor Agonists Are Associated With Lower Early Revision Risk Compared to Bariatric Surgery Following Total Hip Arthroplasty: A Retrospective Cohort Study

Background

Obesity is a major modifiable risk factor in total hip arthroplasty (THA), associated with increased complications. While bariatric surgery has been the standard for massive weight loss, glucagon-like peptide-1 receptor agonists (GLP-1 RAs) are increasingly used. Purposes: We sought to answer 2 questions: (1) Are early postoperative complication risks different between THA patients using GLP-1 RAs versus prior bariatric surgery? (2) Do differences persist at mid-term follow-up?